Form 4: ResMed Director John Hernandez Receives Equity Grant

ResMed Director John Hernandez was granted 1,073 Restricted Stock Units, increasing his direct beneficial ownership to 5,118 shares.

Summary

• John Hernandez, a Director of ResMed Inc. (RMD), acquired 1,073 shares of ResMed Common Stock.
• The acquisition occurred on November 20, 2025, and represents Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0, indicating they are part of compensation.
• Following this transaction, Mr. Hernandez directly beneficially owns 5,118 shares.
• The RSUs will vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, as it increases their stake in the company and aligns their financial interests with those of shareholders, promoting long-term value creation.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.

Future Outlook

The Restricted Stock Units granted to Director John Hernandez are scheduled to vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Industry Context

Insider equity grants, such as Restricted Stock Units, are a common form of executive and director compensation across various industries, including medical technology, to incentivize long-term performance and align leadership interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be viewed positively as it aligns the director's financial interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.

Next Steps

• The Restricted Stock Units will vest in full on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation. While it represents a positive signal of alignment between management and shareholders, a single, expected insider transaction of this nature typically does not provide sufficient new information to warrant a change in an investment recommendation for the stock. The fundamental outlook for ResMed Inc. remains unchanged based solely on this filing.

Keywords

ResMed, RMD, John Hernandez, Director, Restricted Stock Units, RSUs, Insider Transaction, Equity Grant, Beneficial Ownership